QHSLab (OTCQB:USAQ) Issues Unaudited Financial and Operational Update Ahead of January 2026 Investor Session
MWN-AI** Summary
QHSLab Inc. (OTCQB: USAQ), a digital health infrastructure company, released an unaudited financial and operational update on January 6, 2026, ahead of an investor session scheduled for the same day. The update highlights significant growth and strategic financial maneuvers that position the company positively as it enters 2026.
For the nine months ending September 30, 2025, QHSLab reported a notable revenue of $1.99 million, which marks a robust 32% increase year-over-year. The company's gross profit stood at $1.32 million, reflecting a gross margin of about 66%. Additionally, QHSLab achieved a net operating income of $95,738 before interest, signaling operational viability. As of December 31, 2025, the company reported approximately $630,000 in cash, which reflects its improved cash flow profile.
One of the most significant developments during the fourth quarter of 2025 was the strategic elimination of outstanding convertible debt, which plummeted from approximately $1.4 million to just $20,000. This reduction is anticipated to lower annual interest expenses by over $250,000 moving forward. Management asserts that the company exited 2025 in a cash-flow-positive position, enhancing its financial outlook.
QHSLab's capital structure comprises 13,418,899 shares of common stock, with around 2,429,525 shares available for public trading, positioning the company for future growth. The operational outlook suggests improved leverage and the expectation of reporting net income after certain financial adjustments for the year ending December 31, 2025, contingent upon year-end audits.
Overall, these developments underline QHSLab's commitment to transparency and growth as it prepares for ongoing discussions with investors about its digital health solutions aimed at primary care practices.
MWN-AI** Analysis
As we approach QHSLab Inc.'s January 2026 investor session, recent unaudited financial disclosures suggest encouraging growth in both revenue and operational efficiency. For the nine months ending September 30, 2025, the company reported revenues of $1.99 million, up an impressive 32% year-over-year. This growth trajectory highlights the company's potential in the digital health landscape, especially given its focus on enhancing primary care practices through scalable solutions.
A key investor takeaway is QHSLab’s improved financial health, characterized by the removal of nearly all convertible debt, which has dramatically reduced interest expenses by over $250,000 annually. Entering 2026 with approximately $630,000 in cash bolsters the company's liquidity and operational flexibility, positioning it favorably for future investments or innovations. The reported gross margin of 66% also signifies strong operational efficiency, which may attract investors looking for healthy margins in the competitive healthcare sector.
Additionally, management anticipates a return to net income despite the burden of prior debt. If the company successfully executes its strategies to enhance operational leverage while maintaining revenue growth, it could generate a positive market response as these metrics align favorably with investor expectations for profitability.
Despite these positive indicators, potential investors should maintain caution. The current public float stands at about 2.4 million shares, reflecting various restrictions under Rule 144. This limited liquidity, coupled with the uncertainties inherent in forward-looking statements, poses risks that investors must evaluate.
In summary, while QHSLab exhibits signs of financial robustness and growth potential, prudent investment decisions should factor in market conditions, liquidity constraints, and overall economic factors impacting the healthcare sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Unaudited update reflects revenue growth, positive operating income, removal of convertible debt, and improved cash flow profile entering 2026.
Company reports $1.99 million in revenue for the nine months ended September 30, 2025, up 32% YoY, eliminates convertible debt, and ends the year with approximately $630,000 in cash.
West Palm Beach, FL, Jan. 06, 2026 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health infrastructure company focused on supporting primary care practices, today provided an unaudited business and financial update in advance of a scheduled investor discussion today.
Unaudited Financial Highlights
The following financial information is unaudited and based on the Company’s internal records and most recent publicly reported filings.
• For the nine months ended September 30, 2025, the Company reported revenue of $1.99 million, representing a 32 percent increase year over year.
• Gross profit for the nine months was $1.32 million, reflecting a gross margin of approximately 66 percent.
• Net operating income before interest was $95,738.
• Cash at bank as of December 31, 2025 was approximately $630,000.
Balance Sheet and Capital Structure Update
During the fourth quarter of 2025, the Company continued to increase its revenue run rate and completed actions to simplify its balance sheet and improve its long-term capital structure.
• Outstanding convertible debt has been practically eliminated, reduced from approximately $1.4 million to $20,000.
• The elimination of convertible debt is expected to reduce annual interest expense by more than $250,000 on a forward-looking basis.
• Management believes the Company exited 2025 in a cash-flow-positive operating position.
Capital Structure and Public Float
As of the date of this release, the Company has 13,418,899 shares of common stock outstanding, of which approximately 2,429,525 shares constitute the public trading float.
Included in the outstanding shares are approximately 2,301,565 restricted common shares issued in connection with recent debt conversions, equity financings, and preferred share dividend payments. These shares are subject to Rule 144 restrictions and generally may not be resold into the public market until the applicable six-month holding period has elapsed and other Rule 144 conditions are satisfied.
OTC Markets reflects the Company’s current outstanding share count and public float information consistent with these disclosures.
Operational Outlook
Based on current operating performance and the reduction in interest expense, management believes the Company is positioned for improved operating leverage entering 2026 and expects to report net income after interest, amortization, and depreciation for the year ended December 31, 2025, subject to completion of year-end financial close and audit procedures.
This disclosure is provided to support transparency ahead of upcoming investor discussions and does not constitute guidance. All financial information presented herein is unaudited.
About QHSLab
QHSLab, Inc. (OTCQB: USAQ) is a digital health infrastructure company providing preventive screening, assessment, and workflow solutions for primary care practices. Its platform enables care that occurs outside the exam room, including screening, monitoring, education, and follow-up, to be delivered in a scalable, documented, and reimbursable manner across multiple underdiagnosed conditions.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/QHSLabInc
FAQ**
How does QHSLab Inc. plan to leverage the revenue growth of 32% YoY, particularly in relation to competitive positioning against U S Alcohol Testing Amer Inc USAQ?
With the removal of convertible debt and reduced interest expenses, what specific strategies will QHSLab Inc. implement to enhance profitability compared to U S Alcohol Testing Amer Inc USAQ?
Can management provide insights on how the improved cash flow profile entering 2026 positions QHSLab Inc. relative to U S Alcohol Testing Amer Inc USAQ in terms of investment opportunities?
As QHSLab Inc. reports a $1.99 million revenue and looks ahead, how does it view its market potential compared to U S Alcohol Testing Amer Inc USAQ in the digital health sector?
**MWN-AI FAQ is based on asking OpenAI questions about U S Alcohol Testing Amer Inc (OTC: USAQ).
NASDAQ: USAQ
USAQ Trading
-17.0% G/L:
$0.61 Last:
401 Volume:
$0.614975 Open:
